|
413 Companies |
|
276 Products |
|
276 Products |
|
144 Mechanisms of Action |
|
557 Trials |
|
45749 News |
|
| «12...634635636637638639640641642643644645646» |
- |||||||||| Zarxio (filgrastim-sndz) / Sandoz
New P3 trial: PIONEER: Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim (clinicaltrials.gov) - Jan 12, 2012
P3, N=218, Completed, Sponsor: Sandoz
- thioguanine / Generic mfg.
Trial completion: SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jan 12, 2012
P2, N=50, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed
- Trial termination, Metastases: A Study of LY2584702 in Participants With Advanced Cancer (clinicaltrials.gov) - Jan 9, 2012
P1, N=34, Terminated, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Terminated; The pharmacokinetic properties of the molecule do not allow for further dose escalation or development.
- ||| MK-8242 / Merck (MSD)
Enrollment open: Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650) (clinicaltrials.gov) - Jan 9, 2012
P1, N=86, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Terminated; The pharmacokinetic properties of the molecule do not allow for further dose escalation or development. Not yet recruiting --> Recruiting
- sirolimus / Generic mfg.
Enrollment change, Metastases: Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer (clinicaltrials.gov) - Jan 8, 2012
P1/2, N=54, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=72 --> 54
- Clinical: Metabolomic in Critical Ill Patients (clinicaltrials.gov) - Jan 8, 2012
P=N/A, N=0, Active, not recruiting, Sponsor: Università Vita-Salute San Raffaele
- ||| E7820 / Eisai
Trial initiation date, Metastases: Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer (clinicaltrials.gov) - Jan 5, 2012
P1/2, N=95, Active, not recruiting, Sponsor: Eisai Inc.
N=72 --> 54 Initiation date: Apr 2011 --> Oct 2011
- Rituxan (rituximab) / Roche
Enrollment change: EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Jan 5, 2012
P2, N=80, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Apr 2011 --> Oct 2011 N=60 --> 80
- Farydak (panobinostat) / Secura Bio
Clinical: Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 3, 2012
P1/2, N=80, Recruiting, Sponsor: SCRI Development Innovations, LLC
N=60 --> 80 Not yet recruiting --> Recruiting
- PK/PD data: PTN_POPS: Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care (clinicaltrials.gov) - Jan 3, 2012
P=N/A, N=500, Recruiting, Sponsor: Daniel Benjamin
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
New P2 trial, IO biomarker: Cytomegalovirus Control in Critical Care (clinicaltrials.gov) - Jan 2, 2012
P2, N=141, Recruiting, Sponsor: University Hospital Birmingham NHS Foundation Trust
- || Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial initiation date: Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Dec 30, 2011
P1, N=102, Active, not recruiting, Sponsor: Onconova Therapeutics, Inc.
Not yet recruiting --> Recruiting Initiation date: Sep 2009 --> Dec 2009
- | Enrollment change: The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients (clinicaltrials.gov) - Dec 30, 2011
P3, N=400, Recruiting, Sponsor: Montefiore Medical Center
Initiation date: Sep 2009 --> Dec 2009 N=900 --> 400
- cladribine / Generic mfg.
Enrollment open: Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis (clinicaltrials.gov) - Dec 30, 2011
P2, N=20, Recruiting, Sponsor: Assistance Publique - H
N=900 --> 400 Not yet recruiting --> Recruiting
- | MV-NIS / Vyriad
New P1 trial, Oncolytic virus: Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma (clinicaltrials.gov) - Dec 29, 2011
P1, N=36, Recruiting, Sponsor: Mayo Clinic
- ||| Istodax (romidepsin) / Astellas, BMS
Trial initiation date: A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma (clinicaltrials.gov) - Dec 28, 2011
P2, N=131, Active, not recruiting, Sponsor: Celgene Corporation
Not yet recruiting --> Recruiting Initiation date: Feb 2007 --> Jun 2007
- ||| Istodax (romidepsin) / Astellas, BMS
Enrollment change: A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma (clinicaltrials.gov) - Dec 28, 2011
P2, N=131, Active, not recruiting, Sponsor: Celgene Corporation
Initiation date: Feb 2007 --> Jun 2007 N=65 --> 131
- dusigitumab (MEDI-573) / AstraZeneca
New P1 trial, Combination therapy, Metastases: MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. (clinicaltrials.gov) - Dec 22, 2011
P1, N=6, Completed, Sponsor: MedImmune LLC
- 5-fluorouracil / Generic mfg.
New P1 trial: SJREFU: Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma (clinicaltrials.gov) - Dec 21, 2011
P1, N=27, Recruiting, Sponsor: St. Jude Children's Research Hospital
- TXA-127 / Constant Therap
Trial termination: Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer (clinicaltrials.gov) - Dec 20, 2011
P2b, N=34, Terminated, Sponsor: US Biotest, Inc.
N=65 --> 131 Recruiting --> Terminated
- TXA-127 / Constant Therap
Enrollment change: Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer (clinicaltrials.gov) - Dec 20, 2011
P2b, N=34, Terminated, Sponsor: US Biotest, Inc.
Recruiting --> Terminated N=75 --> 34
- | Farydak (panobinostat) / Secura Bio
Clinical: Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 19, 2011
P1/2, N=80, Recruiting, Sponsor: SCRI Development Innovations, LLC
- |||| carboplatin / Generic mfg., cisplatin / Generic mfg., pemetrexed / Generic mfg.
Trial completion: A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer (clinicaltrials.gov) - Dec 15, 2011
P1/2, N=120, Completed, Sponsor: Eli Lilly and Company
N=75 --> 34 Active, not recruiting --> Completed
- || tasisulam (LY573636) / Eli Lilly
Enrollment closed: A Safety Study in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Dec 14, 2011
P1, N=230, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- dacarbazine / Generic mfg.
Enrollment change, FDG PET, Metastases: Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma (clinicaltrials.gov) - Dec 13, 2011
P2, N=80, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting N=40 --> 80
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche
Trial completion, Metastases: A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen (clinicaltrials.gov) - Dec 13, 2011
P1, N=55, Completed, Sponsor: Genentech
N=40 --> 80 Active, not recruiting --> Completed
- | Pixuvri (pixantrone) / Servier, Rituxan (rituximab) / Roche
New P1/2 trial: IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 12, 2011
P1/2, N=36, Recruiting, Sponsor: Anne Beaven, MD
- | clofarabine / Generic mfg.
Enrollment change: A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Dec 8, 2011
P2a, N=36, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed N=48 --> 36
- New P1 trial, Metastases: Single Dose of Intravenous rhTNF-? and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Dec 8, 2011
P1, N=21, Suspended, Sponsor: Ludwig Institute for Cancer Research
- Cyramza (ramucirumab) / Eli Lilly
Trial completion, Metastases: Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas (clinicaltrials.gov) - Dec 8, 2011
P1, N=6, Completed, Sponsor: Eli Lilly and Company
N=48 --> 36 Active, not recruiting --> Completed
- | clofarabine / Generic mfg.
Trial completion: A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Dec 8, 2011
P2a, N=36, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || alisertib (MLN8237) / Puma
Enrollment change, Metastases: A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2011
P1, N=87, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed N=60 --> 87
- Trial withdrawal: Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Dec 4, 2011
P1, N=0, Withdrawn, Sponsor: Barbara Ann Karmanos Cancer Institute
N=60 --> 87 Recruiting --> Withdrawn
- Enrollment change: Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Dec 4, 2011
P1, N=0, Withdrawn, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Withdrawn N=24 --> 0
- ||||| ipatasertib (RG7440) / Roche, apitolisib (GDC-0980) / Roche
New P2 trial: Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy (clinicaltrials.gov) - Dec 4, 2011
P2, N=262, Recruiting, Sponsor: Genentech
- | New P1/2 trial: Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma (clinicaltrials.gov) - Nov 30, 2011
P1/2, N=76, Recruiting, Sponsor: Loyola University
- cefepime hydrochloride / Generic mfg.
New P1 trial: Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (clinicaltrials.gov) - Nov 30, 2011
P1, N=70, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
- | Turalio (pexidartinib) / Daiichi Sankyo
Enrollment open: Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Nov 24, 2011
P1/2, N=45, Recruiting, Sponsor: Plexxikon
N=24 --> 0 Not yet recruiting --> Recruiting
- || Neulasta (pegfilgrastim) / Roche
New P3 trial: STUDY OF SAFETY AND EFFICACY OF PEGYLATED APOFILGRASTIM VERSUS US AND EU LICENSED NEULASTA (EUDRACT) - Nov 23, 2011
P3, N=600, Ongoing, Sponsor: Apotex Inc
- | New P4 trial: Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on CD11b in Septic Neonates (clinicaltrials.gov) - Nov 20, 2011
P4, N=90, Completed, Sponsor: Ain Shams University
- | Simulect (basiliximab) / Novartis, 90Y basiliximab - National Cancer Institute / Bethesda
New P1/2 trial: Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov) - Nov 20, 2011
P1/2, N=64, Recruiting, Sponsor: City of Hope Medical Center
- ||| fosamprenavir / Generic mfg.
Enrollment change: Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (clinicaltrials.gov) - Nov 17, 2011
P2, N=75, Completed, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting N=48 --> 75
- | Trial completion: A Study of LY2584702 in Solid Tumors (clinicaltrials.gov) - Nov 17, 2011
P1, N=15, Completed, Sponsor: Eli Lilly and Company
N=48 --> 75 Active, not recruiting --> Completed
- cladribine / Generic mfg.
New P2 trial: Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis (clinicaltrials.gov) - Nov 15, 2011
P2, N=20, Recruiting, Sponsor: Assistance Publique - H
- Yervoy (ipilimumab) / BMS
New P1 trial, Surgery, Metastases: Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Nov 15, 2011
P1, N=28, Recruiting, Sponsor: Northwestern University
- ||| PF-04691502 / Pfizer, gedatolisib (PF-05212384) / Celcuity
Enrollment open: Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer (clinicaltrials.gov) - Nov 15, 2011
P1, N=120, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Somavert (pegvisomant) / Pfizer, figitumumab (CP-751,871) / Novartis
Enrollment change, Metastases: Figitumumab Combined With Pegvisomant For Advanced Solid Tumors (clinicaltrials.gov) - Nov 14, 2011
P1, N=24, Terminated, Sponsor: Pfizer
Not yet recruiting --> Recruiting N=60 --> 24
- ||||| Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 14, 2011
P2, N=84, Recruiting, Sponsor: Amgen Research (Munich) GmbH
- ||| buparlisib (AN2025) / Novartis, Adlai Nortye
New P1 trial, Metastases: A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) - Nov 9, 2011
P1, N=53, Recruiting, Sponsor: Emory University
- lenalidomide / Generic mfg.
Enrollment open: Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Nov 6, 2011
P1/2, N=89, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
N=60 --> 24 Not yet recruiting --> Recruiting